YiLin Cloud Secures Tens of Millions in Series A Funding to Accelerate Clinical Evidence Support Platform; Files IPO Prospectus

VCBeat recently learned that Yilinyun Technology Co., Ltd. (“Yilinyun”) has announced the completion of its tens-of-millions-yuan Series A financing round, exclusively invested by Bayland Capital.

The company stated that this round of financing will be primarily used to further strengthen the development of its R&D, medical affairs, clinical operations, and clinical data science teams, accelerate the realization of a “patient-centric” integrated cloud platform, and enhance after-sales service capabilities.

Delivering more reliable solutions for clinical trial endpoint assessment via an intelligent cloud platform.To date, Yilinyun’s clinical evidence-supported cloud platform has taken shape, encompassing eCOA, CTMS, eTMF, EDC, RTSM, Resource Management, and other modules.

Yi Lin Yun’s headquarters is located in the Shenzhen Bay Technology and Ecology Park, the core of the Guangdong-Hong Kong-Macao Greater Bay Area, with a research and development center in Chengdu and offices in Beijing and Shanghai.

Currently, Yilin Cloud has established partnerships with multiple leading innovative pharmaceutical companies and CROs. As the exclusive strategic partner of Signant Health in Greater China, it leverages top-tier international expert resources to continuously expand its services in scale administration, back-end medical support, rater training, and endpoint assessment for international multi-center clinical trials, thereby enhancing the precision of clinical trial endpoints.

Dr. Qin Long, CEO of Yilin CloudIndicates：“Empowering new drug R&D with technological innovation is a core DNA of the Yilin Yun team."The digitalization and intelligent transformation of clinical research will continue to drive and accelerate the new drug development process, bringing more opportunities to the industry. Following this round of financing, the company will further increase its investment in platform R&D, medical and scientific support, and after-sales service operations. We firmly believe that high-quality platform-based products and high-value-added services are the foundation of Yilin Cloud’s development."

Dai Yiren, Partner at Bayland Capital, stated“We are honored to participate in this round of financing. Bayland Capital focuses on investments in the biopharmaceutical sector, with a particular emphasis on global biopharmaceutical R&D services and technological innovation platforms.”The founding team of Yilin Cloud boasts extensive expertise in the digital transformation of clinical research and possesses a profound understanding of the industry’s pain points. The design of its integrated platform is innovative, forward-looking, and open, and has already garnered recognition from the industry.“The future holds great promise. We look forward to working closely with Yilin Cloud to accelerate the integration of more high-quality resources and talent, thereby supporting our clients’ innovative drug R&D efforts.”

Yi Lin Yun, with the mission of “bringing effective treatments to patients through technological innovation,” is a healthcare and life sciences enterprise rooted in China and serving the global market.

Yi Lin Yun provides an integrated, all-in-one cloud platform and clinical trial endpoint assessment technologies across various therapeutic areas, building a globally leading, patient-centric SaaS cloud platform for clinical evidence support. This helps pharmaceutical companies and research institutions both in China and abroad improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.

Bayland Capital, established in 2019, specializes in equity investments within the biopharmaceutical sector. Leveraging a unique industry perspective and extensive experience in industry operations, scientific research, management, and capital markets, the Bayland Capital team conducts global investments with a focus on leading global biopharmaceutical R&D services and technology innovation platforms, biotechnology companies, medical device manufacturers, and other related entities. Bayland Capital is committed to serving as a bridge linking life sciences, the health industry, and capital, while striving to be a trusted long-term partner.